Literature DB >> 26611600

Viral Vector-Based Modeling of Neurodegenerative Disorders: Parkinson's Disease.

D Luke Fischer1,2,3, Sara E Gombash1,4, Christopher J Kemp1, Fredric P Manfredsson5, Nicole K Polinski1,3, Megan F Duffy1,3, Caryl E Sortwell6.   

Abstract

Gene therapy methods are increasingly used to model Parkinson's disease (PD) in animals in an effort to test experimental therapeutics within a more relevant context to disease pathophysiology and neuropathology. We have detailed several criteria that are critical or advantageous to accurately modeling PD in a murine model or in a nonhuman primate. Using these criteria, we then evaluate approaches made to model PD using viral vectors to date, including both adeno-associated viruses and lentiviruses. Lastly, we comment on the consideration of aging as a critical factor for modeling PD.

Entities:  

Keywords:  Adeno-associated virus; Dopamine; Lentivirus; Leucine-rich repeat kinase 2; Lewy body; PTEN-induced putative kinase 1; Parkin; Parkinson’s disease; Striatum; Substantia nigra; Tyrosine hydroxylase; α-synuclein

Mesh:

Year:  2016        PMID: 26611600     DOI: 10.1007/978-1-4939-3271-9_26

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  10 in total

Review 1.  How can rAAV-α-synuclein and the fibril α-synuclein models advance our understanding of Parkinson's disease?

Authors:  Laura A Volpicelli-Daley; Deniz Kirik; Lindsay E Stoyka; David G Standaert; Ashley S Harms
Journal:  J Neurochem       Date:  2016-05-04       Impact factor: 5.372

2.  Impact of age and vector construct on striatal and nigral transgene expression.

Authors:  Nicole K Polinski; Fredric P Manfredsson; Matthew J Benskey; D Luke Fischer; Christopher J Kemp; Kathy Steece-Collier; Ivette M Sandoval; Katrina L Paumier; Caryl E Sortwell
Journal:  Mol Ther Methods Clin Dev       Date:  2016-12-07       Impact factor: 6.698

3.  Subthalamic Nucleus Deep Brain Stimulation Does Not Modify the Functional Deficits or Axonopathy Induced by Nigrostriatal α-Synuclein Overexpression.

Authors:  D Luke Fischer; Fredric P Manfredsson; Christopher J Kemp; Allyson Cole-Strauss; Jack W Lipton; Megan F Duffy; Nicole K Polinski; Kathy Steece-Collier; Timothy J Collier; Sara E Gombash; Daniel J Buhlinger; Caryl E Sortwell
Journal:  Sci Rep       Date:  2017-11-27       Impact factor: 4.379

4.  Silencing Alpha Synuclein in Mature Nigral Neurons Results in Rapid Neuroinflammation and Subsequent Toxicity.

Authors:  Matthew J Benskey; Rhyomi C Sellnow; Ivette M Sandoval; Caryl E Sortwell; Jack W Lipton; Fredric P Manfredsson
Journal:  Front Mol Neurosci       Date:  2018-02-13       Impact factor: 5.639

5.  Quality Over Quantity: Advantages of Using Alpha-Synuclein Preformed Fibril Triggered Synucleinopathy to Model Idiopathic Parkinson's Disease.

Authors:  Megan F Duffy; Timothy J Collier; Joseph R Patterson; Christopher J Kemp; D Luke Fischer; Anna C Stoll; Caryl E Sortwell
Journal:  Front Neurosci       Date:  2018-09-04       Impact factor: 4.677

6.  BDNF provides many routes toward STN DBS-mediated disease modification.

Authors:  D Luke Fischer; Caryl E Sortwell
Journal:  Mov Disord       Date:  2018-11-15       Impact factor: 10.338

Review 7.  Emerging Therapeutic Strategies for Parkinson's Disease and Future Prospects: A 2021 Update.

Authors:  Noha A Gouda; Ahmed Elkamhawy; Jungsook Cho
Journal:  Biomedicines       Date:  2022-02-03

Review 8.  Adeno-Associated Virus Expression of α-Synuclein as a Tool to Model Parkinson's Disease: Current Understanding and Knowledge Gaps.

Authors:  Taylor E Huntington; Rahul Srinivasan
Journal:  Aging Dis       Date:  2021-07-01       Impact factor: 6.745

Review 9.  Current Experimental Studies of Gene Therapy in Parkinson's Disease.

Authors:  Jing-Ya Lin; Cheng-Long Xie; Su-Fang Zhang; Weien Yuan; Zhen-Guo Liu
Journal:  Front Aging Neurosci       Date:  2017-05-03       Impact factor: 5.750

Review 10.  New Tools for Epilepsy Therapy.

Authors:  Chiara Falcicchia; Michele Simonato; Gianluca Verlengia
Journal:  Front Cell Neurosci       Date:  2018-05-29       Impact factor: 5.505

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.